Paper Details

  1. Home
  2. Paper Details

Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2.

Author: AndersonJaclyn K, DokoupilovaEva, KeisermanMauro, LertratanakulApinya, McCaskillReva M, MeasePhilip J, PanganAileen L, PappKim, TillettWilliam, TsujiShigeyoshi, Van den BoschFilip, WangXin, ZhongSheng, ZuegerPatrick

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

A randomized, placebo-controlled trial of 642 patients with psoriatic arthritis (PsA) who had inadequate response or intolerance to at least one biologic disease-modifying antirheumatic drug (DMARD) evaluated the efficacy of upadacitinib. Both upadacitinib 15 mg and 30 mg were more effective than placebo in improving signs and symptoms of PsA over 24 weeks. The rates of treatment-emergent adverse events were generally similar to placebo for upadacitinib 15 mg, while upadacitinib 30 mg was associated with higher rates.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Upadacitinib is a Janus kinase inhibitor under evaluation for the treatment of psoriatic arthritis (PsA). We evaluated upadacitinib in patients with PsA and prior inadequate response or intolerance to at least one biologic disease-modifying antirheumatic drug (DMARD). METHODS: In this 2...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7892371/

データ提供：米国国立医学図書館（NLM）

Upadacitinib: A New Hope for Refractory Psoriatic Arthritis

Psoriatic arthritis (PsA), like a stubborn desert sandstorm, can be a relentless and challenging condition. This study, like a determined researcher seeking a new treatment solution, explores the efficacy of upadacitinib, a Janus kinase inhibitor, in patients with PsA who have not responded adequately to conventional therapies. The researchers, like skilled artisans carefully crafting a new tool, meticulously evaluated the drug's impact on symptoms and disease progression.

Upadacitinib: A Potential Breakthrough

The study revealed that upadacitinib demonstrated significant improvement in PsA symptoms, particularly in patients who had previously failed to respond to biologic disease-modifying antirheumatic drugs (bDMARDs). This discovery, like finding a hidden spring in a barren desert, offers new hope for individuals struggling with this condition. The study highlights the potential for upadacitinib to become a valuable treatment option for a broader range of PsA patients.

Navigating PsA Treatment: A Personalized Approach

This research, like a compass guiding us through the complex landscape of PsA treatment, emphasizes the importance of individualizing care. By understanding the specific needs and responses of each patient, healthcare providers can tailor treatment plans and optimize outcomes. This personalized approach, like a skilled Bedouin navigating a complex desert terrain, requires careful consideration of individual factors and a commitment to ongoing evaluation and adjustment.

Dr.Camel's Conclusion

This study, like a shimmering oasis in the desert of PsA, offers a glimmer of hope for individuals seeking effective treatment. The development of upadacitinib, a promising new therapeutic agent, could potentially transform the management of PsA, providing a more personalized and effective approach to care. This research reminds us of the power of innovation and the importance of continuous exploration in the quest to improve patient outcomes.

Date :
  1. Date Completed 2022-06-27
  2. Date Revised 2022-07-01
Further Info :

Pubmed ID

33272960

DOI: Digital Object Identifier

PMC7892371

Related Literature

Article Analysis
・Effective treatment of psoriatic arthritis
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.